|
Gastric Adenocarcinoma
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Mammary Neoplasms
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Colorectal Neoplasms
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Mammary Neoplasms
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
Mammary Neoplasms
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy.
|
24516025 |
2014 |
|
Mammary Neoplasms
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.
|
22046346 |
2011 |
|
Malignant neoplasm of breast
|
|
0.030 |
GeneticVariation
|
BEFREE |
Here, we presented a heavy pretreated and harbored HER2 V777L mutation de novo stage IV Luminal B (HER2 unamplified) breast cancer patient who achieved an unexpected good response to trastuzumab combined with vinorelbine therapy.
|
31118664 |
2019 |
|
Breast Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Here, we presented a heavy pretreated and harbored HER2 V777L mutation de novo stage IV Luminal B (HER2 unamplified) breast cancer patient who achieved an unexpected good response to trastuzumab combined with vinorelbine therapy.
|
31118664 |
2019 |
|
Breast Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
This was identified in one of six cases of a HER2-amplified breast cancer, both pre- and post-treatment; however, HER2 V777L was not identified in 14 responders who were treated with trastuzumab.
|
27900589 |
2017 |
|
Breast Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
In an independent data set, 2 of 9 (22.2%) ERBB2/HER2-negative BrCa switched to ERBB2/HER2-positive with 1 BrM acquiring ERBB2/HER2 amplification and the other showing metastatic enrichment of the activating V777L ERBB2/HER2 mutation.
|
27926948 |
2017 |
|
Malignant neoplasm of breast
|
|
0.030 |
GeneticVariation
|
BEFREE |
In an independent data set, 2 of 9 (22.2%) ERBB2/HER2-negative BrCa switched to ERBB2/HER2-positive with 1 BrM acquiring ERBB2/HER2 amplification and the other showing metastatic enrichment of the activating V777L ERBB2/HER2 mutation.
|
27926948 |
2017 |
|
HER2 gene amplification
|
|
0.030 |
GeneticVariation
|
BEFREE |
In an independent data set, 2 of 9 (22.2%) ERBB2/HER2-negative BrCa switched to ERBB2/HER2-positive with 1 BrM acquiring ERBB2/HER2 amplification and the other showing metastatic enrichment of the activating V777L ERBB2/HER2 mutation.
|
27926948 |
2017 |
|
Malignant neoplasm of breast
|
|
0.030 |
GeneticVariation
|
BEFREE |
This was identified in one of six cases of a HER2-amplified breast cancer, both pre- and post-treatment; however, HER2 V777L was not identified in 14 responders who were treated with trastuzumab.
|
27900589 |
2017 |
|
HER2 gene amplification
|
|
0.030 |
GeneticVariation
|
BEFREE |
This is the first report to show that HER2 V777L is coincident with HER2-amplification in breast cancers that have developed trastuzumab resistance.
|
27900589 |
2017 |
|
HER2 gene amplification
|
|
0.030 |
GeneticVariation
|
BEFREE |
ERBB2/HER2 alterations were identified in 5 pmucBC (23 %): ERBB2 amplification was found in 3 of 3 cases (100 %) that were HER2+ by IHC and/or FISH; 1 pmucBC was negative for HER2 overexpression by IHC, but positive for amplification by CGP; and 2 pmucBC harbored the ERBB2 substitutions D769Y and V777L (one sample also featured ERBB2 amplification).
|
26762307 |
2016 |
|
Carcinoma breast stage IV
|
|
0.010 |
GeneticVariation
|
BEFREE |
Although HER2-unamplified MBC patients do not regularly benefit from anti-HER2 target therapy, HER2 V777L mutation detected by next-generation sequencing from ctDNA may present as a predictive biomarker for anti-HER2-based strategy therapy in HER2-negative MBC patients.
|
31118664 |
2019 |
|
Luminal B Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Here, we presented a heavy pretreated and harbored HER2 V777L mutation de novo stage IV Luminal B (HER2 unamplified) breast cancer patient who achieved an unexpected good response to trastuzumab combined with vinorelbine therapy.
|
31118664 |
2019 |